ASP Isotopes (NASDAQ:ASPI) Issues Earnings Results, Misses Expectations By $0.05 EPS

ASP Isotopes (NASDAQ:ASPI) issued its quarterly earnings results on Wednesday. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.05), Zacks reports. The company had revenue of $4.89 million during the quarter, compared to analysts’ expectations of $2.25 million. ASP Isotopes had a negative return on equity of 239.22% and a negative net margin of 2,181.62%.

ASP Isotopes Price Performance

ASP Isotopes stock opened at $7.50 on Thursday. The company’s 50 day simple moving average is $9.60 and its 200-day simple moving average is $8.79. The company has a debt-to-equity ratio of 3.53, a quick ratio of 14.56 and a current ratio of 14.72. ASP Isotopes has a 1 year low of $3.65 and a 1 year high of $14.49. The company has a market capitalization of $700.55 million, a price-to-earnings ratio of -5.91 and a beta of 3.28.

Insider Buying and Selling

In other news, Director Michael Gorley sold 64,000 shares of the stock in a transaction dated Tuesday, September 30th. The shares were sold at an average price of $9.75, for a total transaction of $624,000.00. Following the sale, the director owned 81,360 shares of the company’s stock, valued at approximately $793,260. This represents a 44.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Paul Elliot Mann sold 81,077 shares of the company’s stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $8.39, for a total value of $680,236.03. Following the sale, the chief executive officer directly owned 8,084,191 shares in the company, valued at $67,826,362.49. This represents a 0.99% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 473,699 shares of company stock valued at $4,225,902 over the last quarter. 21.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On ASP Isotopes

Several hedge funds and other institutional investors have recently made changes to their positions in ASPI. Quantbot Technologies LP purchased a new stake in shares of ASP Isotopes in the 3rd quarter valued at approximately $34,000. BNP Paribas Financial Markets lifted its holdings in ASP Isotopes by 84.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company’s stock worth $41,000 after buying an additional 2,548 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in shares of ASP Isotopes by 96.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 10,890 shares of the company’s stock worth $80,000 after acquiring an additional 5,353 shares in the last quarter. Legal & General Group Plc increased its holdings in shares of ASP Isotopes by 30.4% in the 3rd quarter. Legal & General Group Plc now owns 8,377 shares of the company’s stock valued at $81,000 after acquiring an additional 1,953 shares during the last quarter. Finally, FORA Capital LLC acquired a new stake in shares of ASP Isotopes during the 2nd quarter worth about $107,000. Hedge funds and other institutional investors own 16.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Loop Capital set a $15.00 price objective on ASP Isotopes in a report on Monday, October 27th. Weiss Ratings reiterated a “sell (e+)” rating on shares of ASP Isotopes in a research report on Thursday, October 30th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $11.00 price target on shares of ASP Isotopes in a research note on Wednesday, September 17th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $13.00.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.